Single-Dose Oxytocin Did Not Enhance Reward Processing in the Brain in Autism

This was a randomized, double-blind, placebo-controlled, crossover fMRI study. Participants received either 24 IU intranasal oxytocin or placebo in separate sessions and performed an incentive delay task measuring neural activity during anticipation and receipt of both monetary and social rewards. Both frequentist and Bayesian statistical analyses were used to evaluate results.

Oxytocin has been widely promoted as a potential treatment for social difficulties in autism, partly based on its role in social bonding. This well-designed negative study is important because it provides rigorous evidence against the hypothesis that single-dose oxytocin broadly enhances reward circuitry in autism, helping to set realistic expectations and redirect research toward more targeted approaches.

The oxytocin-autism hypothesis has generated enormous research interest and public hope. However, accumulating evidence from rigorous trials like this one suggests the relationship is more complex than initially thought. Single-dose oxytocin may not be sufficient to modulate reward circuits, pointing toward the need for different dosing regimens, longer treatment durations, or more targeted patient selection to identify who might benefit.

The study tested only a single dose, so chronic oxytocin effects remain unknown. Only men without intellectual impairment were included, limiting generalizability to women and those with co-occurring intellectual disability. The sample size (37 per group), while reasonable, may still have been insufficient to detect subtle effects. The incentive delay task may not capture all aspects of social reward processing relevant to autism.